No Data
Oppenheimer points out the next "trend" for weight loss drugs: oral over-the-counter medication.
The competition to develop oral weight-loss drugs is intensifying.
Why Viking Therapeutics Stock Was So Healthy on Wednesday
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
Next Frontier in Anti-obesity Landscape: Oral GLP-1s With Potential OTC Switch
Viking Therapeutics Analyst Ratings
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138